Anúncio
Anúncio

ATOS

ATOS logo

Atossa Therapeutics, Inc. Common Stock

0.65
USD
Patrocinado
-0.01
-1.07%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

0.64

-0.01
-1.08%

Relatórios de Lucros ATOS

Rácio de surpresa positiva

ATOS separação 20 de 31 últimas estimativas.

65%

Próximo Relatório

Data do Próximo Relatório
23 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.06
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/
-14.29%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/
+20.00%

Atossa Therapeutics, Inc. Common Stock earnings per share and revenue

On 12 de nov. de 2025, ATOS reported earnings of -0.07 USD per share (EPS) for Q3 25, missing the estimate of -0.06 USD, resulting in a -2.94% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.74% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analistas forecast an EPS of -0.06 USD, with revenue projected to reach -- USD, implying an diminuir of -14.29% EPS, and aumentar of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
AngioDynamics, Inc.
Report Date
06 de jan. de 2026 Para Q2 26
Estimativa
-$0.10
Real
$0.00
Surpresa
+100.00%
FAQ
For Q3 2025, Atossa Therapeutics, Inc. Common Stock reported EPS of -$0.07, missing estimates by -2.94%, and revenue of $0.00, 0% as expectations.
The stock price moved down -1.74%, changed from $0.83 before the earnings release to $0.81 the day after.
The next earning report is scheduled for 23 de mar. de 2026.
Based on 5 analistas, Atossa Therapeutics, Inc. Common Stock is expected to report EPS of -$0.06 and revenue of -- for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio